Quidel Corp
Suletud
10.31 -9.48
Ülevaade
Aktsiahinna muutus
24h
Min
10.29
Max
11.39
Sissetulek | 39M -92M |
|---|---|
Müük | -104M 620M |
Kasumimarginaal | -14.811 |
Töötajad | 6,500 |
Soovitused | Neutraalne |
|---|---|
12 kuu keskmine prognoos | +8.87% upside |
Järgmine tulemuste avaldamine | 4. aug 2026 |
|---|
Turukapital | -140M 560M |
|---|---|
Eelmine avamishind | 19.79 |
Eelmine sulgemishind | 10.31 |
Quidel Corp Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Quidel Corp Prognoos
Hinnasiht
By TipRanks
8.87% tõus
12 kuu keskmine prognoos
Keskmine 12.03 USD 8.87%
Kõrge 13 USD
Madal 11 USD
Põhineb 6 Wall Streeti analüütiku instrumendi Quidel Corp 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
Ärikasum
$
Ettevõttest Quidel Corp
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
